Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ZyVersa Therapeutics (ZVSA)
NASDAQ:ZVSA
RESEARCH TOOLSreports
ZyVersa Therapeutics (ZVSA) Stock Price & Analysis
102 Followers
ZVSA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.50 - $90.65
Previous Close$0.58
Volume329.48K
Average Volume (3M)2.52M
Market Cap
$4.83M
Enterprise Value$1.70M
Total Cash (Recent Filing)$3.14M
Total Debt (Recent Filing)$8.66K
Price to Earnings (P/E)>-0.1
Beta0.62
Next Earnings
May 10, 2024EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-189.61
Shares Outstanding7,594,863
10 Day Avg. Volume355,721
30 Day Avg. Volume2,524,938
Standard Deviation0.34
R-Squared0.00865
Alpha-0.14
Financial Highlights & Ratios
Price to Book (P/B)0.44
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.02
Forecast
1Y Price Target
$8.00Price Target Upside1285.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
ZyVersa Therapeutics News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation of a Phase 2a trial of VAR 200 in patients with diabetic kidney disease represents a significant milestone for ZyVersa.
Financial HealthWith Funding in Place, CRO Selected For Phase 2a Trial of VAR 200 in DKD; Affirm Buy
Medical ResearchResearch suggests inflammasome inhibition with IC 100 could ameliorate systemic inflammation in obesity.
Bears Say
Clinical And Regulatory RiskClinical trial failures or equivocal data could significantly impact the stock, as well as the inability to secure regulatory approval for key products such as VAR 200 or IC 100.
Financial Valuation RiskAn increase in the discount rate used in the rNPV model to 18% reflects growing concerns about the company's financial stability and could lead to a lower valuation of the stock.
Funding And Trial RiskA chronic lack of funding raises concerns that clinical trials might be underpowered, potentially leading to less conclusive results and negatively affecting the stock.
---
Ownership Overview
54.30%
Insiders
0.06% Mutual Funds
2.12% Other Institutional Investors
43.52% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ZVSA FAQ
What was ZyVersa Therapeutics’s price range in the past 12 months?
ZyVersa Therapeutics lowest stock price was $0.50 and its highest was $90.65 in the past 12 months.
What is ZyVersa Therapeutics’s market cap?
Currently, no data Available
When is ZyVersa Therapeutics’s upcoming earnings report date?
ZyVersa Therapeutics’s upcoming earnings report date is May 10, 2024 which is in 9 days.
How were ZyVersa Therapeutics’s earnings last quarter?
ZyVersa Therapeutics released its earnings results on Mar 25, 2024. The company reported -$14.86 earnings per share for the quarter, missing the consensus estimate of -$1.03 by -$13.83.
Is ZyVersa Therapeutics overvalued?
According to Wall Street analysts ZyVersa Therapeutics’s price is currently Undervalued.
Does ZyVersa Therapeutics pay dividends?
ZyVersa Therapeutics does not currently pay dividends.
What is ZyVersa Therapeutics’s EPS estimate?
ZyVersa Therapeutics’s EPS estimate is -$0.37.
How many shares outstanding does ZyVersa Therapeutics have?
ZyVersa Therapeutics has 7,594,863 shares outstanding.
What happened to ZyVersa Therapeutics’s price movement after its last earnings report?
ZyVersa Therapeutics reported an EPS of -$14.86 in its last earnings report, missing expectations of -$1.03. Following the earnings report the stock price went down -2.439%.
Which hedge fund is a major shareholder of ZyVersa Therapeutics?
Among the largest hedge funds holding ZyVersa Therapeutics’s share is Saba Capital Management. It holds ZyVersa Therapeutics’s shares valued at N/A.
---
ZyVersa Therapeutics Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (1285.16% Upside)
$8.00 (1285.16% Upside)
Hedge Fund Trend
Decreased
By 17.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 2.1%
Last 30 Days ▲ 2.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-98.98%
12-Months-Change
Fundamentals
Return on Equity
-177.00%
Trailing 12-Months
Asset Growth
-81.34%
Trailing 12-Months
Company Description
ZyVersa Therapeutics
Larkspur Health Acquisition Corp is a blank check company.
---
ZVSA Stock 12 Months Forecast
Average Price Target
$8.00
▲(1285.16% Upside)
Technical Analysis
Best Analysts Covering ZVSA
1 Year
1 Year Success Rate
0/5 ratings generated profit
1 Year Average Return
-54.26%
reiterated a buy rating last month
Copying Ed Arce's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -54.26% per trade.
---